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Enhanced rates of programmed cell death (apoptosis) have been detected in T cells and B cells from human immunodefi-
ciency virus type 1 (HIV-1)-infected individuals. To evaluate the possible relevance of this event to HIV pathogenesis and
disease progression, apoptosis in CD4/ T lymphocytes and CD19/ B lymphocytes, viral load, and neutralizing antibody
titers were assayed in HIV-1-infected slow progressors and progressors. A correlation was found between progressive
disease and apoptosis of CD4/ T cells. The extent of apoptosis in CD4/ cells was similar in slow progressors and seronega-
tive control subjects. By contrast, we found elevated levels of B-cell apoptosis in all HIV-1-infected individuals compared
with seronegative control subjects, with a tendency toward increased levels of apoptosis with progressive disease. Apoptosis
in CD4/ T cells and CD19/ B cells correlated with viral RNA levels in plasma. Furthermore, higher rates of B-cell apoptosis
were observed in individuals with poor neutralizing activity against a panel of six clinical HIV-1 isolates. From these results
we conclude that the extent of apoptosis in cultured CD4/ cells and CD19/ cells appears to parallel the decline in CD4
cell counts in infected individuals. The finding of a relation between apoptosis in B cells and poor neutralizing capacity
suggests that apoptosis may be related to loss of immune function. A role for apoptosis in the pathogenesis of AIDS is
also supported by the strong correlation between viral load and rates of apoptosis in CD4/ T cells. q 1997 Academic Press
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INTRODUCTION sons with slow disease progression remain asymptom-
atic for 8–10 years or more and have stable CD4 cell
Programmed cell death, or apoptosis, is an active cell counts. Extensive study of the characteristics of these
deletion process involved in the development and main- subjects has revealed unusually vigorous immune re-
tenance of tissue and organ homeostasis. Dysregulated sponses, including cytotoxic T cells and virus-neutraliz-
apoptosis has been suggested to lead to diseases such ing antibodies, and a low viral burden (Haynes et al.,
as cancer and autoimmune disorders (Thompson, 1995). 1996). To test the hypothesis that apoptosis may be
Inappropriate induction of apoptosis in T cells has also linked to clinical progression we measured apoptosis in
been postulated to be involved in the continuous loss of CD4/ T lymphocytes and CD19/ B lymphocytes obtained
CD4/ T cells during infection with human immunodefi- from two groups of HIV-1-infected individuals with differ-
ciency virus type 1 (HIV-1). Not only CD4/ T cells, but ent disease courses. We also analyzed the relationship
also CD8/ T cells and B cells from HIV-1-infected individ- between apoptosis in these cell types and the levels of
uals have been found to undergo apoptosis in culture, viral RNA and virus-neutralizing antibodies in plasma.
and cellular death increases upon stimulation of the cells
(Carbonari et al., 1994; Estaquier et al., 1994; Groux et
MATERIALS AND METHODSal., 1992; Meyaard et al., 1992; Samuelsson et al., 1997).
Cell death thus occurs also in cells that are not the major Study subjects
targets for virus replication, and its significance in the
pathogenic process is not thoroughly understood. HIV-1 seropositive subjects were followed with regular
Some individuals infected with HIV-1 appear to be pro- check-ups at the Department of Infectious Diseases at
tected against the development of immunodeficiency de- Huddinge Hospital, Stockholm. We included consecutive
spite many years of infection (Buchbinder et al., 1994; cases who had been infected for more than 8 years. A
Learmont et al., 1992; Sheppard et al., 1993). These per- group of 10 individuals met our criteria for slow prog-
ressors: they were asymptomatic and maintained CD4
cell counts above 400/ml at study entry. None of these1 To whom correspondence and reprint requests should be ad-
individuals were given antiretroviral treatment. In addi-dressed at Microbiology and Tumorbiology Center, Karolinska Institute,
tion, 13 individuals with CD4 cells counts 200/ml andS-171 77 Stockholm, Sweden. Fax: /46 8 33 13 99. E-mail: francesca.
chiodi@mtc.ki.se. with symptomatic disease (progressors) were included
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TABLE 1
Clinical Characteristics of HIV-1 Infected with Slow Progressive and Progressive Disease
CD4 CD19 Months of
Age Years of Route of counts countsb CDC antiretroviral
Subjects (years)/Sex infection infectiona (No./ml) (No/ml) stagec treatmentd
1 40/M 11 IV 770 200 A1 —
2 42/M 8 IV 460 110 A2 —
3 37/F 10 IV 480 140 A2 —
4 39/M 11 IV 1020 280 A1 —
5 51/M 12 HS 730 210 A1 —
6 39/M 10 IV 760 460 A1 —
7 43/F 10 IV 860 30 A1 —
21 38/F 16 IV 350 ND A2 —
22 37/M 12 IV 580 460 A1 —
23 42/M 11 IV 840 ND A1 —
8 38/M 11 HS 220 120 B2 4/AZT/3TC
19 41/M 12 HS 260 ND B2 11/AZT/3TC
10 40/M 9 HS 250 ND B2 11/AZT/dlv/placebo
11 40/M 11 HS 200 ND C3 41/AZT
12 48/M 11 HS 130 70 C3 18/AZT/3TC
13 43/M 12 HS 10 260 C3 2/AZT/3TC
14 46/M 10 HS 5 ND C3 10/AZT/3TC
15 41/M 10 HS 40 20 B3 11/AZT/3TC/placebo
16 40/F 12 HET 110 30 C3 12/AZT/ddI
17 41/F 12 IV 40 110 C3 5/AZT/3TC
18 45/M 10 IV 140 60 B3 —
19 42/M 12 HS 230 ND B3 7/D4T/3TC/IND
20 47/M 11 HS 50 ND C3 5/D4T/ddI/3TC
Note. Peripheral blood samples were obtained from HIV-1 infected individuals attending the Department of Infectious Diseases at Huddinge
hospital.
a IV, intravenous drug user; HS, homosexual; HET, heterosexual.
b Reference value for CD19/ cells: 50–440/ml. ND, not done.
c Patients were classified according to the 1993 revised CDC classification.
d AZT, zidovudine; 3TC, lamivudine; dlv, delavirdine; ddI, dideoxyinosine; d4T, stavudine; IND, indinavir.
in the study. Clinical characteristics of the patients are Measurement of apoptosis
presented in Table 1. Negative control samples were Quantification of apoptotic cells was performed by flow
obtained from 9 HIV seronegative healthy subjects. cytometry after binding of FITC-conjugated annexin V
(annexin V-FITC) to phosphatidylserine exposed on
Cell preparation and culture apoptotic cells (Koopman et al., 1994). The cells (1 1
106/sample) were washed once in PBS and resuspendedFresh blood samples were obtained and peripheral
blood mononuclear cells (PBMC) were prepared by cen- in 10 ml/ml annexin V-FITC (Bender Med System) in
HEPES buffer consisting of 10 mM HEPES/NaOH, pHtrifugation over a Ficoll-Hypaque density gradient
(Lymphoprep, Nycomed). CD19-positive B cells were iso- 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 , 1.8 mM CaCl.
After incubation at /47 for 15 min the cells were washedlated using anti-CD19-coated paramagnetic beads
(MACS system, Miltenyi Biotec GmbH, Germany) ac- once in HEPES buffer and fixed in 1% paraformaldehyde
in PBS. The FITC fluorescence was measured using acording to the manufacturer’s instructions. The CD19-
depleted population was further used for selection of Becton Dickinson flow cytometer and the percentage of
annexin V-positive cells was calculated using CellquestCD4-positive cells using anti-CD4-coated microbeads.
The purity of the cell populations was determined using software. Cells staining positive with annexin-V FITC also
exhibited decreased forward scatter and increased sideflow cytometric analysis after staining with R-phycoery-
trin-Cy5-conjugated anti-CD19 antibodies and fluores- scatter properties, reflecting the typical morphological
changes of apoptotic cells. The cells from 14 individualscein isothiocyanate (FITC)-conjugated anti-CD4 (Dako
A/S, Denmark), respectively. Typically, cell populations were also analyzed after staining with propidium iodide
according to the method of Nicoletti (Nicoletti et al.,were ¢95% pure. After separation, the cells were cul-
tured overnight in RPMI 1640 medium supplemented with 1991). This technique identifies hypodiploid nuclei indi-
cating apoptotic cell death. The results from the two10% fetal calf serum (FCS) and antibiotics and then used
for analysis of apoptosis. methods correlated with each other, although higher lev-
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els of apoptosis were detected using annexin V (data neutralizing antibody titers. The results from these analy-
ses are shown in Fig. 1 and Table 2.not shown).
The percentages of cultured CD4/ T cells and CD19/
B cells in apoptosis are shown in Fig. 1A. HIV-1-infectedVirus neutralization
individuals harbored lymphocytes primed to undergo
Neutralization tests were performed using six HIV-1 apoptosis in culture, and on examination of the HIV-1-
clinical isolates from infected individuals residing in Swe- infected subjects according to disease outcome 8–10
den (J8761, 8632, and 9553), Italy (Ita1 and Ita2), and years after infection, distinctive differences appeared.
Brazil (Bra1). Virus stocks were prepared by passaging High levels of apoptosis in the CD4/ T-cell population
the virus in PBMC (Albert et al., 1990). To avoid interfer- were seen in patients with progressive disease (6–62%)
ence in the neutralization assay by antiretroviral thera- compared to seronegative controls (3.0–5.8; P 0.0005).
peutics or virus-inhibiting chemokines present in plasma, The percentage of apoptotic CD4/ cells from slow prog-
we purified the immunoglobulin G (IgG) fraction from 1 ressors (2.8–13%) was not significantly different from that
ml plasma from the HIV-1-infected subjects using protein of seronegative controls. As previously demonstrated
G affinity columns (HiTrap affinity columns, Pharmacia (Carbonari et al., 1994; Samuelsson et al., 1997), B cells
Biotech) according to the manufacturer’s instructions. from HIV-1-infected individuals underwent apoptosis in
IgG preparations were dialyzed against PBS and filtered culture. Again, the more advanced clinical condition (CD4
through a 0.02-mm sterile filter. Protein concentrations in cell counts 200/ml) was associated with high levels of
these preparations ranged between 1 and 5 g/L, i.e., a apoptosis in B cells (22.5–67%) compared to seronega-
5- to 10-fold lower concentration than IgG in plasma. tive controls (8–19%; P 0.0005). Also slow progressors
Neutralization assays were performed with 2-fold serial had significantly higher levels of B-cell apoptosis than
dilutions of purified IgG, essentially as previously de- seronegative controls (14–61%; P  0.005). There was
scribed, using 10–50 50% tissue culture infectious doses a trend toward increased levels of apoptosis with clinical
of HIV-1 and phytohemagglutinin-P (PHA)-stimulated hu- progression, but the difference did not reach statistical
man PBMC as target cells (Scarlatti et al., 1993). Culture significance (P  0.05). Representative flow cytometric
supernatants were harvested on day 7 and tested in an data from controls and HIV-1-infected individuals are
HIV-1 p24 antigen assay (Sundqvist et al., 1989). The shown in Fig. 2.
neutralizing titer was defined as the reciprocal of the IgG We studied the relationship between apoptosis in T
dilution giving 90% reduction of optical density in p24 cells and B cells and parameters which have been shown
ELISA compared to wells containing virus alone. Titers to be associated with clinical progression (Cao et al.,
above 20 were considered positive. A serum from an 1995). The levels of HIV-1 RNA copies in plasma and
asymptomatic Swedish subject (SE1785) selected for virus-neutralizing IgG titers were analyzed in the patients.
high neutralizing activity was used as positive control Plasma RNA load in slow progressors and progressors
serum. is presented in Fig. 1B. All individuals with progressive
disease received treatment with antiretroviral drugs,
Viral load whereas the slow progressors were not given these
drugs. The combination treatment with inhibitors of re-Measurement of HIV-1 RNA copies per milliliter of
verse transcriptase can be expected to significantly re-plasma was performed by quantitative PCR using an Am-
duce the viral load in these individuals (Hammer, 1996);plicor HIV-1 monitor test (Roche).
in spite of this there was a two log difference in the
median values between the two groups (P  0.05). TheStatistical analysis
viral copy number in progressors ranged between 500
and 4,740,900 copies/ml, but in slow progressors theThe Kruskal–Wallis and Mann–Whitney tests were
viral load also varied considerably (500–137,600 cop-used for statistical analyses.
ies/ml). We compared the percentages of apoptotic cell
death in CD4/ cells and CD19/ cells with plasma viralRESULTS
load in the HIV-1-infected subjects. For both of these cell
types, a correlation was found between the extent ofWe have studied two groups of patients with HIV-1
infection for more than 8 years: slow progressors with apoptosis and the HIV-1 RNA copy number in plasma
(Fig. 3). The correlation between CD4 cell apoptosis andCD4 cell counts 400/ml and patients with progressive
disease with CD4 200/ml (Table 1). HIV-1-infected indi- plasma viral load was highly significant (P  0.0005).
To investigate the possible impact of increased ratesviduals were also compared with seronegative healthy
controls. The majority of HIV-1 infected individuals had of apoptosis in B cells and CD4/ T cells on the anti-HIV-
1 humoral immune responses, we measured neutralizingB-cell levels (CD19/ cells) within the normal limit. The
parameters that were evaluated in this study included activity against a panel of clinical HIV-1 isolates. To en-
sure that the neutralizing activity we detected was in factapoptosis in CD4/ and CD19/ cells, viral load, and virus-
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FIG. 1. (A) Levels of apoptosis in PBMC subsets from HIV-1-infected persons and seronegative controls. CD4/ cells and CD19/ cells were
separated using immunomagnetic beads. The percentages of apoptotic cells were measured by annexin V staining and flow cytometry. PBMC were
obtained from slow progressors with CD4 cell counts 400/ml (2), progressors with CD4 cell counts 200/ml (3), and seronegative healthy control
subjects (1). Statistical analyses were performed using the Kruskal –Wallis test. The horizontal bars indicate the median values. (B) Viral load in
slow progressors (2) compared to progressors (3), as measured by quantitative PCR. The horizontal bars indicate the median values. Comparisons
which reached statistical signifiance are indicated.
mediated by antibody, we used the IgG fraction from tralizing activity was detected in individuals with both
normal and low CD4 cell counts (Fig. 4C). Similarly, thereplasma. As shown in Table 2, IgG from 5 of 7 slow pro-
gressors showed neutralizing activity against at least one was no statistical difference between the percentages
of apoptotic CD4/ cells in patients grouped according tovirus isolate in this assay. Neutralizing activity could be
detected in 4 of 10 individuals with progressive disease; neutralizing capacity (Fig. 4A). Interestingly, an inverse
relation was observed between presence of cross-neu-the difference between the two groups was, however,
not statistically significant. Figure 4 shows CD4 cell tralizing activity in plasma and priming for apoptosis in
CD19/ B cells (Fig. 4B; P  0.05, Mann–Whitney test).counts and levels of apoptosis in CD4/ T cells and
CD19/ B cells in HIV-1-infected individuals in relation to Significantly higher percentages of apoptosis were de-
tected in cultured B cells from individuals who lackedthe capacity to neutralize primary HIV-1 isolates. Neu-
TABLE 2
Neutralization of Primary HIV-1 Isolates by Purified IgG from Slow Progressors and Progressors
Subject J8761 J8632 J9553 Ita1 Ita2 Bra1
Slow progressors
1 — 20 — — — —
2 — — — 40 — —
3 — — — — — —
4 — 20 — 40 — —
5 20 80 20 40 — 80
6 — — — — — —
7 — 40 — — — 20
Progressors
8 — 40 — 40 — —
9 — — — — — —
10 — 80 — — — —
11 — — — — — —
12 20 160 20 — — 40
13 — 20 — — — —
14 — — — — — —
15 — — — — — —
16 — — — — — —
17 — — — — — —
Control serum 40 640 320 640 40 640
Note. Results are shown as the reciprocal of 90% inhibitory dilutions. A dash indicates a titer of 20. Control serum was obtained from an
asymptomatic HIV-1-infected individual and used without IgG purification.
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FIG. 2. Representative histograms of flow cytometric analyses of annexin V-FITC-stained CD4/ and CD19/ cells from seronegative healthy control
subjects (1), HIV-1-infected slow progressors with CD4 cell counts 400/ml (2), and progressors with CD4 cell counts 200/ml (3). M1 indicates
annexin V-positive cells.
neutralizing antibody against any of the HIV-1 isolates sponses. Which of these features are in fact responsible
tested than in B cells from individuals with a detectable for the lack of disease development is not clearly under-
virus-neutralizing response. By contrast, absolute CD19 stood. Probably several factors determine the balance
counts were not related to neutralizing activity (Tables 1 between virus and host during the asymptomatic phase
and 2). of the disease. Viral genotypes which have been associ-
ated with a lower pathogenicity are those with defective
accessory genes (Kirchhoff et al., 1995; Michael et al.,DISCUSSION
1995). In addition, host genetic factors appear to be im-
portant; recently a higher frequency of CCR5 deletionViral and immunological parameters of slow prog-
heterozygotes was found among slow progressorsressors have been analyzed by several investigators in
than among progressors (Dean et al., 1996; Huangorder to understand why these HIV-1-infected individuals
et al., 1996).remain healthy (Cao et al., 1995; Montefiori et al., 1996;
Our finding of a relation between apoptosis and clini-Pantaleo et al., 1995; Rinaldo et al., 1995). Although the
cal disease confirms the results of previous investiga-findings vary somewhat according to the cohort under
tors. Pandolfi et al. found a correlation among cellularstudy, the most consistent findings appear to be a low
viral load and strong humoral and cellular immune re- death and disease severity and CD4 counts (Pandolfi et
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al., 1993). No priming for apoptosis in CD4 cells was
detected in chronic infections that did not lead to deple-
tion of CD4/ cells and immunodeficiency, whereas in-
creased rates of CD4 cell apoptosis were detected in
rhesus macaques experimentally infected with SIV
mac251 (Estaquier et al., 1994; Gougeon et al., 1993). By
contrast, other investigators did not find a correlation
between apoptotic T-cell death and disease progression
or stage of disease (Meyaard et al., 1994; Muro-Cacho
et al., 1995). Some of the discrepancies in these studies
may be due to methodological differences. For the pres-
ent investigation fresh blood samples and positive selec-
tion with immunomagnetic beads were used. We have
previously observed that differences between groups of
patients are accentuated on bead separation, indicating
that this procedure may, either specifically or nonspecifi-
cally, stimulate the cells (unpublished observation). We
have, however, consistently found elevated levels of
apoptosis in both CD4- and CD19-positive cells in HIV-
1-infected individuals even in cells unaffected by this
procedure.
In this context it is interesting that viral load correlated
with the extent of apoptosis in cultured CD4 cells and
B cells, cells which are not the major target for virus
replication. In particular the extent of CD4 cell apoptosis
correlated strongly with viral load. These results support
the notion that the virus provokes extensive immune acti-
vation and priming of lymphocytes for apoptosis. A model
in which the presence of a large amount of virus pro-
motes a continuous immune activation is also supported
by studies showing a correlation between HIV-1 RNA
levels and markers of immune activation, CD30, TNFa,
and sTNFa receptors (Bilello et al., 1996; Rizzardi et al.,
1996). In a recent study by Gummuluru et al., infection
of macaques with the highly pathogenic SIV variant
SIVsmmPBj14 caused extensive immune activation and
apoptosis in the intestinal lymphoid tissue, which is also
the site for viral replication (Gummuluru et al., 1996).
Interestingly, the majority of apoptotic cells were not pro-
ductively infected by SIV.
We investigated whether the abnormal induction of
apoptosis could be related to immunological dysfunc-FIG. 3. Correlation between viral load and percentages of apoptotic
tions. In all HIV-1-infected individuals, including slowCD4/ cells and CD19/ cells, respectively. Apoptosis in the lymphocyte
subsets and viral load were measured as described under Materials progressors, we found elevated levels of B-cell apoptosis
and Methods. Open circles represent slow progressors and closed compared with seronegative controls. A trend toward
circles progressors. loss of neutralizing antibodies against diverse HIV-1 iso-
lates has been reported to occur in subjects with pro-
gressive disease (Cao et al., 1995; Montefiori et al., 1996),al., 1995). Moreover, higher rates of cellular death were
found in individuals who progressed during follow-up. In although this is not a consistent finding (Harrer et al.,
1996). In the present study, lack of neutralizing activityaddition the extent of apoptosis induced by agonistic
anti-Fas monoclonal antibody correlated inversely with was not primarily associated with low CD4 cell counts
but rather with higher levels of B-cell apoptosis. Further-CD4 cell count (Katsikis et al., 1995). The results that we
obtained can also be compared to those reported by more, the absolute CD19 counts per se did not correlate
with neutralizing capacity. This suggests that apoptosisinvestigators who used nonhuman primate models of
pathogenic or nonpathogenic lentiviral infection (Esta- may indeed have an effect on the functions of B cells,
on accessory cell function or directly on antibody produc-quier et al., 1994; Gougeon et al., 1993; Schuitemaker et
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FIG. 4. Relation between virus-neutralizing capacity and apoptosis in CD4/ cells, apoptosis in CD19/ cells, and CD4 cell counts. Neutralization
assays were performed with purified IgG against a panel of six primary HIV-1 isolates. Apoptosis was measured in bead-purified CD4/ cells and
CD19/ cells using annexin V (see Materials and Methods). The levels of apoptosis in CD4/ cells (A) and CD19/ cells (B) and CD4 cell counts (C)
are presented for subjects with positive neutralization against ¢1 virus isolate (pos NT) and subjects with negative neutralization (neg NT). Statistical
analyses were performed with the Mann–Whitney test. NS, not significant. The horizontal bars indicate the median values.
tion. The finding that B cells carrying a specific immuno- viral production (Boise et al., 1995; Groux et al., 1992;
Levine et al., 1996). In vivo manipulation of CD28 mayglobulin heavy chain family (VH3) were deleted during
HIV-1 infection may support this hypothesis (Berberian thus increase CD4/ T-cell proliferation and limit viral
spread. Recently, CD28 stimulation together with CD3et al., 1991).
HIV-1 infection leads to apoptosis both in in vitro cul- stimulation was shown to have an additional effect on
susceptibility to virus infection by down-regulating thetures and in lymphocytes from infected individuals cul-
tured ex vivo. The findings of a correlation between expression of CCR5 (Carroll et al., 1997). Other ap-
proaches to block apoptosis are immune modulationapoptosis and disease progression support but do not
formally prove that apoptosis is an important part of the through cytokines (IL-12, IL-2, and IL-10), interference
with the Fas–Fas ligand signaling, and inhibition of pro-pathogenetic process. The two groups of patients in-
cluded in the present study differed not only in CD4 teases involved in downstream signaling (Estaquier et
al., 1996; Glynn et al., 1996). In summary, the finding of acounts and viral load but also in clinical status (occur-
rence of opportunistic infections) and antiretroviral treat- correlation between apoptosis and disease progression
certainly warrants further exploration of the mechanismsment. The impact of these factors cannot be assessed
in a study such as this one. In order to clarify whether of these events, which may lead the way to diverse thera-
peutic measures directed toward the prevention ofapoptosis plays a major role in HIV pathogenesis,
blocking of the apoptotic process may be attempted. In apoptosis during HIV-1 infection.
fact, reduction of immune activation and activation-in-
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